INTI on OTC

Inhibitor Therapeutics, Inc.

American pharmaceutical preparations company, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

TickerINTI on OTC¹
IndustryPharmaceutical Preparations¹
HeadquartersTampa, Florida¹
Incorporated inDE²
Business address4830 W. Kennedy Blvd., Suite 600, Tampa, Fl 33609²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Revenue³⁴$0 in 2021

Operating income³⁴⁵-$325.4K in 2021−88% since 2019

Net income³⁴⁵-$298.6K in 2021−89% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
Research and development	$1.7M	$1.8M
General and administrative	$1.7M	$1.9M
Total expenses	$3.4M	$3.7M
Loss from operations	-$3.4M	-$3.7M
Interest income	$126.3K	$318.2K
Net loss	-$3.3M	-$3.3M
Basic net loss per share	-$0.02	-$0.02
Diluted net loss per share	-$0.02	-$0.02
Weighted average common stock shares outstanding - basic	172.5M shares	172.3M shares
Weighted average common stock shares outstanding - diluted	172.5M shares	172.3M shares

Total assets³⁴⁵$58.8K in 2021−93% since 2019

Total liabilities³⁴⁵$3.7M in 2021+7% since 2019

Shareholders’ equity⁴⁵⁹-$3.6M in 2021+43% since 2019

Cash⁴⁵$30.6K in 2021−96% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁸

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$2.4M	$5.6M
Prepaid expenses and other assets	$71.5K	$87.8K
Total current assets	$2.4M	$5.7M
Operating lease right-of-use assets	$64.3K
Total assets	$2.5M	$5.7M
Accounts payable	$51.5K	$15.9K
Accrued expenses and other liabilities	$690.1K	$693.7K
Current portion of operating lease obligations	$24.7K
Total current liabilities	$766.3K	$709.6K
Deferred revenue	$3.0M	$3.0M
Operating lease obligations, less current portion	$36.9K
Total liabilities	$3.8M	$3.7M
Common stock, $0.0001 par value; 500,000,000 shares authorized; 172,573,545 and 172,323,545 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	$17.3K	$17.2K
Additional paid-in capital	$54.1M	$54.1M
Accumulated deficit	-$55.4M	-$52.1M
Total stockholders (deficit) equity	-$1.3M	$2.0M	$5.3M
Total liabilities and stockholders (deficit) equity	$2.5M	$5.7M
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	500.0M shares	500.0M shares
Common stock, shares issued	172.6M shares	172.3M shares
Common stock, shares outstanding	172.6M shares	172.3M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$2.4M	$5.6M
Prepaid expenses and other assets	$71.5K	$87.8K
Total current assets	$2.4M	$5.7M
Operating lease right-of-use assets	$64.3K
Total assets	$2.5M	$5.7M
Accounts payable	$51.5K	$15.9K
Accrued expenses and other liabilities	$690.1K	$693.7K
Current portion of operating lease obligations	$24.7K
Total current liabilities	$766.3K	$709.6K
Deferred revenue	$3.0M	$3.0M
Operating lease obligations, less current portion	$36.9K
Total liabilities	$3.8M	$3.7M
Common stock, $0.0001 par value; 500,000,000 shares authorized; 172,573,545 and 172,323,545 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	$17.3K	$17.2K
Additional paid-in capital	$54.1M	$54.1M
Accumulated deficit	-$55.4M	-$52.1M
Total stockholders (deficit) equity	-$1.3M	$2.0M	$5.3M
Total liabilities and stockholders (deficit) equity	$2.5M	$5.7M
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	500.0M shares	500.0M shares
Common stock, shares issued	172.6M shares	172.3M shares
Common stock, shares outstanding	172.6M shares	172.3M shares

Cash from operations³⁴⁵-$220.4K in 2021−92% since 2019

Dividends paid³$0 in 2020

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
Net loss	-$3.3M	-$3.3M
Stock-based compensation	$23.4K	$40.2K
Non-cash lease expense	$792
Prepaid expense and other assets	$16.3K	$21.4K
Accounts payable and other current liabilities	$28.5K	$44.5K
Net cash used in operating activities	-$3.2M	-$3.2M
Net decrease in cash and cash equivalents	-$3.2M	-$3.2M
Operating right-of-use assets obtained in exchange for lease obligations	$86.4K

Compare Inhibitor Therapeutics, Inc. with another company

Leadership

Who has led Inhibitor Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

President

Chief financial officer

2010201520202025

Chief executive officerFrancis E. Odonnell Jr. Aug 4, 2026 to now¹⁰
Chief executive officerGarrison J. Hasara Aug 21, 2013 to Aug 21, 2013¹¹
Chief executive officerNicholas J. Virca Aug 21, 2013 to Dec 28, 2020¹²
Chief executive officerNick Hagan Feb 13, 2007 to Feb 13, 2007¹³
Chief executive officerPaul D'Sylva Feb 13, 2007 to Feb 13, 2007¹⁴
Chief executive officerRobert B. Harris Feb 8, 2006 to Jan 3, 2007¹⁵
ChairE. Brendan Magrab Nov 30, 2016 to Mar 15, 2018¹⁶
ChairFrancis E. Odonnell Jr. Aug 16, 2013 to Jun 20, 2016¹⁷
ChairWilliam X. Guo Oct 7, 2008 to Oct 7, 2008¹⁸
PresidentNicholas J. Virca Aug 21, 2013 to Dec 28, 2020¹²
PresidentRobert B. Harris Feb 8, 2006 to Jan 6, 2009¹⁵
Chief financial officerJames A. McNulty May 16, 2024 to now¹⁹
Chief financial officerGarrison J. Hasara Feb 6, 2015 to Dec 28, 2020²⁰

Board members and other officers (23)

OfficerFrancis E. Odonnell Jr. Dec 22, 2022 to Dec 22, 2022²¹
OfficerJames A. McNulty Dec 22, 2022 to May 17, 2023²²
ControllerJames H. Brennan Feb 8, 2006 to Jan 6, 2009²³
Senior VP/SecretaryThomas R. Reynolds Feb 8, 2006 to Jan 6, 2009²⁴
Board memberMichael Allen Jerman May 16, 2024 to now²⁵
Board memberRonald E. Osman Aug 29, 2023 to now²⁶
Board memberFrancis E. Odonnell Jr. Dec 22, 2022 to now²¹
Board memberMichelle Yanez Dec 22, 2022 to now²⁷
Board memberNiraj Vasisht Dec 22, 2022 to now²⁸
Board memberDebra Peattie Nov 1, 2019 to Dec 28, 2020²⁹
Board memberE. Brendan Magrab Dec 26, 2018 to Feb 5, 2019³⁰
Board memberStefan Cross Jun 26, 2014 to Feb 12, 2018³¹
Board memberRichard Dana Ono Jul 7, 2014 to Dec 28, 2020³²
Board memberW. Mark Watson Jul 7, 2014 to Dec 28, 2020³³
Board memberNicholas J. Virca Aug 21, 2013 to Aug 21, 2013¹²
Board memberJames D. Causey Feb 6, 2008 to Feb 6, 2008³⁴
Board memberPaul D'Sylva Feb 13, 2007 to Jan 21, 2010¹⁴
Board memberDaniel O. Hayden Mar 29, 2007 to Mar 29, 2007³⁵
Board memberSamuel P. Sears Jr. Jan 11, 2006 to now³⁶
Board memberJames H. Brennan Feb 8, 2006 to Feb 8, 2006²³
Board memberRobert B. Harris Feb 8, 2006 to May 28, 2008¹⁵
Board memberThomas R. Reynolds Feb 8, 2006 to Jan 3, 2007²⁴
Board memberGerald P. Krueger Apr 21, 2006 to May 16, 2006³⁷

Former names

HedgePath Pharmaceuticals, Inc.Aug 16, 2013 to Aug 12, 2019²
COMMONWEALTH BIOTECHNOLOGIES INCOct 7, 1997 to May 20, 2013²

Timeline

Aug 4, 2026New chief executive Francis E. Odonnell Jr. becomes CEO¹⁰
Aug 21, 2013New chief executive Garrison J. Hasara becomes CEO¹¹
Aug 21, 2013New chief executive Nicholas J. Virca becomes CEO¹²
Feb 13, 2007New chief executive Nick Hagan becomes CEO¹³
Feb 13, 2007New chief executive Paul D'Sylva becomes CEO¹⁴
Feb 8, 2006New chief executive Robert B. Harris becomes CEO¹⁵

Filings

70 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 13 major events, 30 insider forms, 3 large holders, 4 other. The latest 20:

Sep 18, 20268-K EDGAR
Aug 17, 2026DEF 14A EDGAR
Aug 14, 202610-Q EDGAR
Aug 4, 20264 EDGAR
Aug 4, 20264 EDGAR
Aug 4, 20264 EDGAR
Aug 4, 20264 EDGAR
Aug 4, 20264 EDGAR
Jun 24, 20264 EDGAR
Jun 1, 20264 EDGAR
May 15, 202610-Q EDGAR
Apr 1, 20268-K EDGAR
Apr 1, 20268-K EDGAR
Mar 26, 202610-K EDGAR
Feb 24, 20268-K EDGAR
Nov 13, 202510-Q EDGAR
Oct 27, 20258-K EDGAR
Sep 15, 2025UPLOAD EDGAR
Aug 13, 202510-Q EDGAR
Jul 22, 2025CORRESP EDGAR

The 70 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Black Robe Capital LLCSC 13D, 1 filing May 23, 2023³⁸
TPB 2012 LLCSC 13G, 1 filing May 23, 2023³⁹
Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012SC 13G, 1 filing May 18, 2023⁴⁰

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARInhibitor Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGARInhibitor Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGARInhibitor Therapeutics, Inc. 10-K for fiscal 2019
4
SEC EDGARInhibitor Therapeutics, Inc. 10-K for fiscal 2020
5
SEC EDGARInhibitor Therapeutics, Inc. 10-K for fiscal 2021
6
SEC EDGARInhibitor Therapeutics, Inc. 10-Q for fiscal 2026
7
SEC EDGARInhibitor Therapeutics, Inc. 10-Q for fiscal 2026
8
SEC EDGARInhibitor Therapeutics, Inc. 10-K filed 2026-03-26: income statement
9
SEC EDGARInhibitor Therapeutics, Inc. 10-K for fiscal 2021
10
SEC EDGARFrancis E. Odonnell Jr., Chief executive officer
11
SEC EDGARGarrison J. Hasara, Chief executive officer
12
SEC EDGARNicholas J. Virca, Chief executive officer
13
SEC EDGARNick Hagan, Chief executive officer
14
SEC EDGARPaul D'Sylva, Chief executive officer
15
SEC EDGARRobert B. Harris, Chief executive officer
16
SEC EDGARE. Brendan Magrab, Chair
17
SEC EDGARFrancis E. Odonnell Jr., Chair
18
SEC EDGARWilliam X. Guo, Chair
19
SEC EDGARJames A. McNulty, Chief financial officer
20
SEC EDGARGarrison J. Hasara, Chief financial officer
21
SEC EDGARFrancis E. Odonnell Jr., Officer
22
SEC EDGARJames A. McNulty, Officer
23
SEC EDGARJames H. Brennan, Controller
24
SEC EDGARThomas R. Reynolds, Senior VP/Secretary
25
SEC EDGARMichael Allen Jerman, Board member
26
SEC EDGARRonald E. Osman, Board member
27
SEC EDGARMichelle Yanez, Board member
28
SEC EDGARNiraj Vasisht, Board member
29
SEC EDGARDebra Peattie, Board member
30
SEC EDGARE. Brendan Magrab, Board member
31
SEC EDGARStefan Cross, Board member
32
SEC EDGARRichard Dana Ono, Board member
33
SEC EDGARW. Mark Watson, Board member
34
SEC EDGARJames D. Causey, Board member
35
SEC EDGARDaniel O. Hayden, Board member
36
SEC EDGARSamuel P. Sears Jr., Board member
37
SEC EDGARGerald P. Krueger, Board member
38
SEC EDGARBlack Robe Capital LLC SC 13D on Inhibitor Therapeutics, Inc.
39
SEC EDGARTPB 2012 LLC SC 13G on Inhibitor Therapeutics, Inc.
40
SEC EDGARRonald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012 SC 13G on Inhibitor Therapeutics, Inc.